

PRESS RELEASE

FOR IMMEDIATE RELEASE: JULY 3RD, 2012

THE CANADIAN INSTITUTES OF HEALTH RESEARCH (CIHR) HAS RANKED NO 1 THE PRECLINICAL DEVELOPMENT OF MICSELON™, A NOVEL CLASS OF DRUG TREATMENT AGAINST URINARY RETENTION AND CONTINENCE PROBLEMS IN SPINAL CORD-INJURED PATIENTS

QUEBEC CITY, CANADA. – Today, we announce that the preclinical development of Micselon™ has begun. CIHR officially decided last March to support financially the Optimization phase study, an important value-creating milestone in the development of a new drug treatment. In its grant application review process (Proof-of-Principle (POP I program), CIHR has ranked Micselon™ as **the best translational life science project in Canada (no 1 among more than twenty projects)**. It is an innovative therapy capable of acutely (within 15-30 min post-administration) triggering episodes of voiding in completely spinal cord-injured animals suffering of bladder control problems. Preclinical data strongly suggest that **Micselon™** is ideally suited to become a *first-in-class* therapy against urinary retention problems and related health problems (urinary tract infections, sepsis, etc.) in patients chronically suffering of spinal cord injury. Nordic Life Science Pipeline is also currently developing another first-in-class treatment discovered at Université Laval by Dr Guertin called Spinalon™ for the induction of walking movements (Clinical Trials phase I/IIa sponsored by the US Department of Defense).

About Micselon™

Discovered in 2009 by Dr. Pierre Guertin, professor at Université Laval, this therapy candidate constitutes a novel class of drug treatment acting as a potent activator of the spinal micturition center. It is constituted of already known molecules which generally lead to faster time of development.

About Spinal Cord Injury

Based on recent estimates, 1.3 million patients currently live with a traumatic spinal cord injury in North America. It has thus become the second most common neurological problem after Alzheimer's disease.

About Nordic Life Science Pipeline Inc.

It is a fast-growing specialty biopharmaceutical company that focuses on developing preclinical- and early clinical-stage therapeutics in the field of neurological diseases and trauma including spinal cord injury and multiple sclerosis.

About Université Laval

Located in Quebec's historic capital, a World Heritage City, Université Laval is one of the first universities in North America (Laval 1663, Harvard 1636). Based on research funding, it ranks among the top ten in Canada.

About U.S. Department of Defense Spinal Cord Injury Research Program

The U.S. Department of Defense and U.S. Army have established a grant application program that financially supports, on a competitive basis, translational research and clinical trials of promising new therapies.

About Canadian Institutes of Health Research

It is the main governmental source of funding for researchers in Life Sciences across Canada.